BELLINI: Venetoclax or placebo with bortezomib and dexamethasone for relapsed/re...
Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia
BELLINI: Venetoclax or placebo with bortezomib and dexamethasone for relapsed/refractory multiple myeloma ( Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia )
25 Sep 2019
Transitioning from bortezomib to ixazomib in patients with multiple myeloma
Dr Habte Yimer - Texas Oncology, Tyler, USA
Transitioning from bortezomib to ixazomib in patients with multiple myeloma ( Dr Habte Yimer - Texas Oncology, Tyler, USA )
23 Sep 2019
Implementing national cancer control plans
Dr Eduardo Cazap and Dr Lisa Stevens
Implementing national cancer control plans ( Dr Eduardo Cazap and Dr Lisa Stevens )
24 Jun 2019
Chemoimmunotherapy or BTK inhibition for patients with CLL
Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany
Chemoimmunotherapy or BTK inhibition for patients with CLL ( Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany )
20 Jun 2019
MOR208 plus lenalidomide in r-r diffuse large B-cell lymphoma
Dr Johannes Düll - University of Würzburg, Würzburg, Germany
MOR208 plus lenalidomide in r-r diffuse large B-cell lymphoma ( Dr Johannes Düll - University of Würzburg, Würzburg, Germany )
20 Jun 2019
Blinatumomab for relapsed/refractory Burkitt's lymphoma
Dr Johannes Düll - University of Würzburg, Würzburg, Germany
Blinatumomab for relapsed/refractory Burkitt's lymphoma ( Dr Johannes Düll - University of Würzburg, Würzburg, Germany )
20 Jun 2019
Using bioinformatics and genomics to treat AML
Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany
Using bioinformatics and genomics to treat AML ( Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany )
20 Jun 2019
The changing landscape of AML
Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany
The changing landscape of AML ( Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany )
20 Jun 2019
CLL14: A chemotherapy-free regimen of venetoclax plus obinutuzumab for CLL
Dr Othman Al-Sawaf - Univesity of Cologne, Cologne, Germany
CLL14: A chemotherapy-free regimen of venetoclax plus obinutuzumab for CLL ( Dr Othman Al-Sawaf - Univesity of Cologne, Cologne, Germany )
20 Jun 2019
Lymphodepleting chemotherapy in order to safely improve the expansion of HER2-CA...
Prof Shoba Navai - Baylor College of Medicine, Houston, USA
Lymphodepleting chemotherapy in order to safely improve the expansion of HER2-CAR T cells in patients with advanced sarcomas ( Prof Shoba Navai - Baylor College of Medicine, Houston, USA )
15 Apr 2019
New developments in soft tissue and bone sarcoma research
Prof Hans Gelderblom - Universiteit Leiden, Leiden, Netherlands
New developments in soft tissue and bone sarcoma research ( Prof Hans Gelderblom - Universiteit Leiden, Leiden, Netherlands )
21 Mar 2019
Patient treatment preferences in relapsed/refractory multiple myeloma
Dr Joseph Mikhael, Prof James Chim and Prof Evangelos Terpos
Patient treatment preferences in relapsed/refractory multiple myeloma ( Dr Joseph Mikhael, Prof James Chim and Prof Evangelos Terpos )
3 Dec 2018